Exercise Stress Tests Can Also Predict Noncardiovascular Deaths

THURSDAY, Sept. 14, 2023 (HealthDay News) -- Abnormalities on an exercise stress test can predict both cardiovascular (CV)- and non-CV-related deaths, according to a study published in the September issue of Mayo Clinic Proceedings.
Nóra Sydó, M.D., Ph.D., from Semmelweis University in Budapest, Hungary, and colleagues sought to identify specific causes of death and determine the prevalence of non-CV deaths in an exercise test referral population and to assess whether exercise test parameters predict non-CV as well as CV deaths. The analysis included nonimaging exercise tests from 13,382 patients (30 to 79 years; September 1993 to December 2010) with mortality determined through January 2016 via Mayo Clinic records and the Minnesota Death Index.
The researchers found that risk for non-CV death was significant for low functional aerobic capacity (hazard ratio, 1.42), abnormal heart rate recovery (hazard ratio, 1.36), and low chronotropic index (hazard ratio, 1.49). An abnormal exercise electrocardiogram (ECG) was not a significant risk. There was a stronger association observed between all exercise test abnormalities, including a composite exercise test score (EX_SCORE), and CV death versus non-CV death, except abnormal exercise ECG.
"Patients should be encouraged to increase physical activity if these prognostic parameters are abnormal, even in the absence of substantial ECG-based CV risk," the authors write.
Related Posts
Get Relief With the Most Common Asthma Medications
FRIDAY, May 12, 2023 (HealthDay News) -- Receiving a diagnosis of asthma may be...
AHA News: Cómo prepararse para incendios forestales y huracanes si ha sobrevivido un ataque cardíaco o derrame cerebral
MIÉRCOLES, 28 de junio de 2023 (American Heart Association News) -- Los...
Trans Identification Not Tied to Worse Pregnancy Outcomes
WEDNESDAY, May 17, 2023 (HealthDay News) -- Transgender, nonbinary, and...
Cemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
WEDNESDAY, May 10, 2023 (HealthDay News) -- Cemiplimab plus chemotherapy results...